Englander Institute for Precision Medicine

Publications

Found 5 results
Author Title Type [ Year(Asc)]
Filters: Author is van der Heijden, Michiel S  [Clear All Filters]
2023
Sternberg CN, Petrylak DP, Bellmunt J, Nishiyama H, Necchi A, Gurney H, Lee J-L, van der Heijden MS, Rosenbaum E, Penel N et al..  2023.  FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on / mRNA Expression.. J Clin Oncol. 41(3):629-639.
2022
de Wit R, Powles T, Castellano D, Necchi A, Lee J-L, van der Heijden MS, Matsubara N, Bamias A, Fléchon A, Sternberg CN et al..  2022.  Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.. Br J Clin Pharmacol. 88(7):3182-3192.
van der Heijden MS, Powles T, Petrylak D, de Wit R, Necchi A, Sternberg CN, Matsubara N, Nishiyama H, Castellano D, Hussain SA et al..  2022.  Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.. Nat Commun. 13(1):1878.
2021
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V et al..  2021.  Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.. Lancet Oncol. 22(4):525-537.
Merseburger AS, Castellano D, Powles T, Loriot Y, Retz M, Voortman J, Huddart RA, Gedye C, van der Heijden MS, Gurney H et al..  2021.  Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.. J Urol. 206(2):240-251.